Human papillomaviruses (HPVs) constitute a large family of DNA viruses which infect mucosal surfaces and cause hyperproliferation [ 11. The group exhibits both a clearly defined epitheliotropism and a strong preference for the anatomical site of infection. Certain virus types infect the anogenital tract and are linked, epidemiologically, to the development of benign and malignant lesions. These virus types are classified as high or low risk according to their association with carcinoma or condyloma (genital warts) [2] . Of the high-risk virus types, HPV 16, 18, 31 and 33 are the most common, HPV 16 being predominant; whereas HPV 6 and 11 are the most common low-risk types.
Interaction of HPV E6 with p53 and associated proteins
Human papillomaviruses (HPVs) constitute a large family of DNA viruses which infect mucosal surfaces and cause hyperproliferation [ 11. The group exhibits both a clearly defined epitheliotropism and a strong preference for the anatomical site of infection. Certain virus types infect the anogenital tract and are linked, epidemiologically, to the development of benign and malignant lesions. These virus types are classified as high or low risk according to their association with carcinoma or condyloma (genital warts) [2] . Of the high-risk virus types, HPV 16, 18, 31 and 33 are the most common, HPV 16 being predominant; whereas HPV 6 and 11 are the most common low-risk types.
HPVs have circular double-stranded genomes of approximately 8 kb containing a small number of open-reading frames. Numerous analyses have indicated that only two HPV-encoded proteins, E6 and E7, are invariably expressed in cervical tumours and tumour-derived cell lines [3, 41. These observations strongly suggest that expression of E6 and E7 contributes to the development, and probably the maintenance, of the malignant phenotype. Studies employing conditional expression of these proteins in vitro have further confirmed that this is required for maintenance of the transformed phenotype [5] .
E6 and E7 from HPV are proteins of approximately 150 and 100 amino acids respectively, and show quite strong amino acid sequence similarity between different HPV types. In rodent systems, E7
proteins from the high-risk (but not the low-risk) virus types have strong transforming properties; whereas E6 has, at best, weak-to-marginal activity their ability to associate with (and presumably inactivate) p5 3 suggested that this association might be important in the oncogenic properties of the viruses. Strong support for this hypothesis has been afforded by studies of primary anogenital carcinomas and cervical carcinoma cell lines. Whereas clonal p53 mutation is rare in HPV-positive primary tumours and cell lines, some (but not all) HPV-negative tumours, and all HPV-negative cell lines, thus far reported, express mutant p53 sequences and protein [16, 171 . These studies suggest that inactivation of p53 is a common step in anogenital carcinogenesis, and can occur either via mutation in the rarely arising HPV-negative cancers, or by complex formation with E6 in HPVpositive tumours. Interestingly, further studies have identified a subset of HPV 16-positive cervical carcinomas which do have mutant p53 sequences, albeit at extremely low frequency in the primary cancers, but clonally in metastatic deposits. These mutant proteins often complex with HPV 16, though markedly less efficiently than wild-type p53 1'53 possesses growth inhibitory and transformation suppressive activities [ 191, which are probably related to the ability of the wild-type protein to regulate transcription both positively and negatively (the latter particularly clearly in the case of promoters containing TATA elements) [20, 211. Genotoxic insult to the cell (produced, for example, by U.V. irradiation and cytotoxic drug treatment) results in the stabilization of p53 and cell-cycle arrest in G1, which has been proposed to be a check-point mechanism allowing the cell to repair damaged I>NA before re-entering the cycle [22] . The mechanism of transcriptional regulation by p53 may involve interaction with components of the general cellular transcription machinery such as Complexing p53 with T or E l b results in the sequestration of p53 into stable complexes in which the p53 is functionally inactivated. This results in a marked increase in the biological half-life of p53 [24] . In contrast, analysis of the half-life of p53 in human keratinocytes that express HPV 16 E6 is consistently lower than in primary, non-I IPVcontaining keratinocytes [ 14, 251. These observations are consistent with the results of studies in vitro which showed that mixing p53 with high-risk I IPV E6 proteins, after translation in reticulocyte lysate, resulted in the rapid degradation of p53 [ 261. No degradation could be detected, however, when p.53 was mixed in reticulocyte lysate with E6 proteins from the low-risk virus types. These results suggested a novel mechanism of action for an oncoprotein; namely, degradation of a cellular tumour suppressor gene product. This has provoked a large effort to define the biochemical pathways involved. Mutational analysis of HPV 16 E6 indicated that sequences in the C-terminus of the protein were required for its association with p53, whereas degradation was dependent on sequences in the N-terminus, thus implying that independent domains of the protein mediate association and degradation [ 131. These observations have been confirmed by using a series of artificial chimaeric proteins, in which portions of HPV E6 are fused inframe to other polypeptides (T. Crook and K. H.
Vousden, unpublished work). The presence of the E6 amino acid sequences confers susceptibility to degradation to the entire molecule. For example, a fusion of E6 with cdc2 rapidly self-degrades in reticulocyte lysate even though cdc2 (which lacks the fused E6 sequences) is stable under identical experimental conditions, indicating an absolute requirement for the E6 sequences. Similar results are observed when E6 is fused to HPV E7. If only a ;mall N-terminal portion of HPV 16 E6 is fused to either cdc2 or E7, this chimaera is also unstable, self-degrading as rates comparable to those observed when full-length E6 is present. In addition, self-degradation occurs if the E6 moiety is either N-or C-terminal to the other polypeptide component of the chimaera, suggesting that discrete domains of the E6 protein mediate the sensitivity to proteolysis. Although the low-risk HPV E6 proteins can also confer self-degradation on such fusion proteins, this property is significantly weaker than that of HPV 16 or HPV 18 (T. Crook and K. H.
Vousden, unpublished work).
The E6-mediated proteolysis of p53 (and selfdegradation of E6 chimaeric proteins) occurs via a ubiquitin-dependent mechanism which requires ATP [26] . Interestingly, mixing E6 and p53 in wheatgerm extract causes no degradation, implying that additional factors (present in the reticulocyte lysate, but not in wheat germ extract) are required for degradation. Ubiquitin is a polypeptide of 76 amino acids (for review, see [28] ). Conjugation of substrates to ubiquitin precedes proteolysis and requires several independent enzymic steps.
Initially, a ubiquitin-activating enzyme (El) catalyses the formation of a thioester bond between the carboxyl group of the C-terminal amino acid residue of ubiquitin and the thiol group in a cysteine residue of El. The activated ubiquitin is then transferred to a cysteine of one of the E2 ubiquitin-conjugating enzymes that catalyses the formation of peptide bonds between the carboxyl group of the ubiquitin and the amino moiety of a lysine residue in the target protein. Additional ubiquitin residues can be ligated to a lysine (at position 48) in the initially ligated ubiquitin, resulting in the formation of multiple chains of ubiquitinated proteins. Ubiquitinated proteins are then degraded by a proteosoma1 complex. The E2 ubiquitin-conjugating proteins are targeted to the protein that is to be ubiquitinated by E3, the so-called ubiquitin ligases.
No substrate-specific €22 or E3 proteins have yet been described or characterized, despite the identification of several natural targets, for ubiquitinmediated proteolysis (including cyclins A and B, etc.) [29] .
In the case of the E6/p53 interaction, however, one of the components of the degradation pathway has been cloned and characterized [30, 311. This factor, designated E6-AP, is a 100 kDa protein, originally identified as a component of reticulocyte lysate, that mediates association between E6 and p53. Although E6-AP is able to associate with E6 proteins in the absence of p53, neither E6 nor E6-AP stably complex with p53 alone, only the triple complex is stable. When such a triple complex forms, the p53, but not the E6-AP nor the E6, is ubiquitinated and degraded. As such, E6 and E6-AP together are acting as a ubiquitin ligase or E3 enzyme. Although the normal function of E b A P remains to be described, it is tempting to speculate that it might function, in unison with a cellular homologue of E6, to regulate levels of p53 protein in non-E6-expressing cells.
What then might be the consequences for the cell of HPV E6 expression and interaction with p53? It is already clear that cells expressing E6 do not show elevated levels of p53 protein in response to genotoxic insult and, as such, do not arrest in G1 in response to DNA-damaging agents. Although the precise implications of this inability to arrest have not been formally analysed, it would not be at all unreasonable to predict that such cells might be more sensitive to the mutagenic effects of DNA damage, with obvious implications for carcinogenesis. In this model, it may be particularly pertinent that HPV E6 appears to preferentially target nascent p53 for degradation. The ability of both high-and low-risk HPV types to modulate the transcriptional regulatory properties of p53 suggests that this activity must play some role in the normal viral life-cycle, perhaps by abrogating p53-mediated cell arrest after viral infection or replication. It may also be that the ability of the E6 proteins from the high-risk HPV types to target p53 for degradation is a key factor in the association of these viruses with cancer rather than with warts.
